Abstract
Introduction
preventive measures. The mutational landscape in NMIBC has recently been described (7-73 9). Furthermore, the APOBEC enzyme family that creates specific mutational signatures in 74 single stranded DNA was shown to be prevalent in bladder cancer and it may fuel the 75 oncogenic transformation (10, 11) . Finally, deep sequencing has recently been used to 76 identify the clonal composition of driver alterations in several cancers (7, 12, 13) .
77
For optimal targeted treatment, it is important to define the ancestral mutations, as these tumor pairs but driver mutations in known tumor suppressors and oncogenes were not 82 predominantly found to be early events. Potential therapeutic targets were identified as 83 both ancestral (shared) and tumor-specific alterations. We found a higher intra-patient 84 variation of the tumor mutation spectrum and frequent APOBEC related mutation 85 signatures in patients with progressive disease. In addition, we found high temporal and 86 DNA samples were mapped to hg19, marked for duplicates, and the alignments were 113 recalibrated and realigned using the picard (http://picard.sourceforge.net/) and GATK 114 suites (14). SNPs were called using GATK HaplotypeCaller and somatic mutations (SNVs) 115 and indels were called using MuTect (15) and the Somatic Indel Detector from GATK.
116
Indels shared by multiple patients were excluded. Functional annotation of mutations were 117 performed using snpEff (16) and SNVs were classified in two categories reflecting the 118 quality of the calls (Cat 1: high and Cat 2: low quality) and four tiers reflecting the impact of 
Phylogenetic tree analysis

137
For all patients with multiple samples, we investigated whether a mutation was present 138 (minimum two reads). This was done for all mutations called as Cat1 in any of the samples 139 from a given patient. We then used the status of each mutation in all samples to find the 140 most probable phylogenetic tree (see Supplementary data for details). Confidence for 141 internal nodes was estimated using bootstrap analysis.
143
Copy-number estimation 144 The sequenza package was used in order to define the copy-number variation from WES 145 data (19). Statistical inference of tumor cell populations using deep exome sequencing 155 PyClone 0.12.7 (12) was used to infer subclonal populations.
156
Data access
161
The sequencing data reported is deposited to the European Genome-phenome Archive
162
(EGA, www.ebi.ac.uk/ega/) under accession EGAS00001001686. Table S2B ). Of these, an average of 110 (5-1259) SNVs (Cat 1 Tier 0+1) 176 and 8 (1-42) indels per tumor had a predicted effect on protein function (Fig. 1B) . The 177 number of mutations was not correlated to sequencing depth. Whole transcriptome 178 sequencing was performed for 71 of the 75 tumors. Samples were sequenced to a mean 179 of 119.6 (7.8-234.6) million mapped reads (Fig. 1A and Supplementary Table S1D) .
180
Clinical data for all patients is summarized in Fig. 1C .
182
Mutational spectrum of tumors from NPD and PD patients 183 In order to evaluate the mutational landscape in bladder cancer, we identified the most 184 frequently mutated genes ( Supplementary Fig. S1 ). A subset of genes with mutations 185 predicted as deleterious (SIFT, PROVEAN and Polyphen2) is presented in Fig. 1D August 3, 2016; DOI: 10.1158/0008-5472.CAN-16-0436 genes in the total patient cohort were, KDM6A (53%), ARID1A (32%), FGFR3 (26%),
188
TP53 (24%), FAT1 (18%), EP300 (16%), RBM10 (16%) and STAG2 (16%) (8, 9, 23) .
189
Compared to studies of MIBC we observed higher mutation rates of KDM6A, ARID1A, 190 FGFR3, FAT1, RBM10 and a lower mutation rate of TP53 (23-26) ( Fig. 1D and 
191
Supplementary Fig. S1 ). There was no significant difference in the mutation rates when 192 comparing the NPD and PD groups (10.3 vs. 14.6 Mutations/Mb; T-test with unequal 193 variances, P=0.20, SNVs Cat1-2 + Indels). Furthermore, no significant difference was 194 observed when considering only the first Ta tumor from each patient in each group (8.8 vs. 195 12.1 Mutations/Mb; T-test with unequal variances, P=0.37, SNVs Cat1-2 + Indels). The 196 variation in the PD group was significantly higher for both comparisons (Bartlett's test, 197 P=0.001 and P=0.004).
198
We observed higher intra-patient variation of the mutational spectrum for metachronous 199 tumors from patients with PD compared to tumors from patients with NPD (Chi2-test,
200
P=0.0013) ( Fig. 2A) , pointing towards additional mutational mechanisms in the PD group, 201 or more variation in repair capacity. Using RNA-Seq data we classified all samples 202 according to a previously reported CIS signature (5) using ConsensusClusterPlus (Fig. 1C) 
203
(27). The CIS signature is associated with high-risk NMIBC (concomitant CIS) and disease 204 progression (28). The CIS signature showed a significant correlation to progression in our 205 study (Chi2-test; P<0.02). When stratifying the mutational analysis based on samples with 206 similar gene expression signatures we did not observe a significant difference in SNVs or 207 indels between the groups (Fig. 1D) .
208
Analyzing the proportions of the individual mutation types (Cat 1) in the initial versus the 209 most recent tumor showed a significant decrease (P<0.017) of C→T mutations in the PD 210 patients ( Supplementary Fig. S2A-D) . When comparing the change in proportion (mean of 1 1 absolute changes) of the individual mutation types from the initial to the most recent tumor,
212
we found a larger change in C→G and C→T (P<0.05) in the PD patients compared to the 213 NPD patients (Supplementary Fig. S2E ). Taking the direction into account only the 214 proportion of C→T mutations remained significant (P<0.01) (Supplementary Fig. S2F ).
215
To gain insight into the mutational processes and signatures we included the 5' and 3' 216 nucleotides and grouped the mutations (Cat 1+2) by context ( Supplementary Fig. S3 )(6).
217
The frequency of the 22 signatures described by Alexandrov et al. (6) was estimated in our 218 75 tumors (Fig. 2B) . In most tumors we observed several signatures (on average, 3.72 219 signatures). The six most abundant signatures (1A, 1B, 2, 6, 12 and 13) were used to 220 define the mutational processes in the samples (Fig. 2C ). Signature 1A was found with a 221 higher frequency in the NPD group compared to the PD group (P<0.0001) whereas no 222 differences between groups were observed for the remaining 5 signatures (Supplementary 223 Fig. S4 ). When focusing only on the first Ta tumors from the two groups, signature 1A was 224 found with a higher frequency in the NPD group compared to the PD group (Mann-Whitney 225 test, P<0.0011), and signatures 1B and 6 were more frequent in the PD group Whitney test, P=0.0270 and P=0.0295 respectively) (Fig. 2D) . Signatures 1A and 1B
227
(characterized by C→T substitutions at NpCpG trinucleotide) are related to age (5-methyl-228 cytosine deamination). However, there was no age difference between patients at the time 229 of the first Ta tumors in the NPD and PD groups (Mann-Whitney test, P=0.12, median age 230 66(39-84) vs. 67(58-80)).
231
When comparing the initial versus the most recent tumor in the two groups, signature 1A 232 was found more frequently in the progressed tumors in the PD group (Wilcoxon Signed-
233
Rank Test, P=0.0048) whereas no difference was observed in the NPD group 234 ( Supplementary Fig. S5 ). The finding that signature 6 (C→T at NpCpG) is present in two 1 2 out of three tumors and is more abundant in the PD group is interesting as this signature is 236 a hallmark of DNA mismatch repair deficiency, not commonly described in BC.
237
Samples were classified according to the APOBEC signature where "high APOBEC" was 238 defined as a contribution of signatures 2 and 13 above 30% and low otherwise. About two 239 thirds of the PD patients were classified as "high APOBEC" in at least one of their tumor 240 samples compared to one third in NPD patients ( Fig. 2E Fisher's exact Test, P=0.009). In PD patients with a classification shift, the "high APOBEC" 244 classification was observed in the initial tumor for half of the patients. Consequently, the 245 data indicates that APOBEC mutational activity is a late event -often tumor-specific.
246
No correlation between the APOBEC score and the mutation rate (Cat 1+2 SNVs/Mb) was Author Manuscript Published OnlineFirst on August 3, 2016; DOI: 10.1158/0008-5472.CAN-16-0436 Conducting this analysis showed that the signature of A3A contributed twice as much as 260 A3B (Fig. 2F) . Interestingly, we found the opposite pattern for the mRNA levels of A3A and 261 A3B (Fig. 2G ), in concert with the A3A enzyme being more mutagenic than A3B. We 262 observed no differences in A3A and A3B across groups.
264
Allele specific expression (ASE) 265 We performed a combined analysis of DNA and RNA to investigate allele specific 266 expression (ASE). First we compared our tumor samples to samples from normal bladder 
Temporal analysis of mutations in individual patients
301
To gain further insight into the accumulation of genetic alterations we constructed 302 phylogenetic trees of disease evolution taking all mutations in Cat1 Tier 0-2 into account.
303
We hypothesized that mutations found in the ancestral branch, i.e. observed in all samples 304 from the same patient, probably characterized the field disease. We observed a tendency 305 for longer ancestral branches (60.8% (31%-85%) vs. 46.5% (14%-87%) of the SNVs; 306 P=0.06) for the NPD patients ( Fig. 3 and Supplementary Fig. S9 ). Furthermore, in four out 
Spatial heterogeneity
321
The analysis of metachronous tumors showed a high degree of intra-patient mutational 322 heterogeneity. We therefore asked whether this reflected high intra-tumor heterogeneity, the heterogeneity observed at the bulk level is also present at the local level.
336
Consequently, a minor fraction of the intra-patient variation appears to be due to intra-337 tumor heterogeneity. Table S5 ). The clonal subpopulations were inferred using PyClone (12) 345 with copy numbers derived from exome-seq data (19). Overall we observed relatively few 346 subclones; in most cases we observed an ancestral clone (defined as a set of mutations) 347 present in all the cells from all tumors and one or two private clones in each of the tumors.
348
The mutations from the private clones were either present in all cells (e.g. patient p09) or 349 only in a subset of the cells (e.g. patient p02) ( Supplementary Fig. S15 to S18). Finally, we looked for potential therapeutic targets in the NPD and the PD group. We one of the highest mutation rates, which entails increased possibility of mutational 385 heterogeneity and increased likelihood of identifying potential therapeutic targets (6, 31).
386
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